

HCL TECHNOLOGIES LTD

IT SERVICES

21 AUG 2019

Company Update

: Rs 1,235

CMP : Rs 1.072 Potential Upside : 15% Relative to Sector : Positive

MARKET DATA

No. of Shares : 135.62 Cr FV (Rs)

Market Cap (Rs Cr.) : 144,482 52-week High / Low

: Rs 1,190/ Rs 920 Avg. Daily vol. (6mth) : 45,28,033 shares Bloomberg Code : HCLT IN Reuters Code : HCLT NS BSE Code : 532281 NSE Code : HCL TECH

Q1 FY20:- Healthy growth momentum to continue

HCL Tech reported strong Q1FY20 numbers. The numbers are much in line with expectations. The revenue in constant currency grew 2.7%.QoQ and 18.4% on YoY basis at Rs. 16,425 crs. However Net income was down by 13.6% QoQ at Rs. 2,220 crs. The mode 1 business vertical grew by 4.1% QoQ, Mode 2 business vertical grew by 3.6% QoQ. Mode 3 business grew by 6.5% QoQ. However operating margins have decline by 193 bps at 17.1% due to higher visa cost, investment in ERS business, and forex loss. The company has given strong revenue growth guidance 14%-16% for FY20 backed by strong deal wins. It maintained FY20 operating margin guidance of 18.5-19.5% citing investments in the digital business. Management commentary on deal wins was positive with 12 transformational deals linked during the quarter. During the quarter the company added 2 clients in 100mn+ vertical, 6 clients in 10mn+ vertical, 10 clients under 5mn + bucket, 10 clients under 1mn + bucket.

Healthy deal wins, higher growth in key business verticals will put HCL Tech on high growth trajectory. We assign 13.8x P/E multiple to its FY21E earnings of Rs. 89.5 per share which gives a target price of Rs. 1,235 per share, an upside of 15%.

Key Highlights

Strong broad based growth, IMS business seen strong revival


IMS vertical has seen strong revival during two previous consecutive quarters. Its strong integrated offering with DRYICE (automation platform) is driving strong wins. Management expects 30% of deals to move to public cloud and next generation services will adopt a hybrid cloud model. Business services, Engineering and R&D services grew by 6.0% QoQ. On Vertical front financial services grew marginally by 0.5% QoQ, Manufacturing sector showed a strong growth 18.4% QoQ, Healthcare sector grew by 2.4%QoQ, Technology and services sector grew 5% QoQ, Retail and CPG remained tepid at -1.4% QoQ growth. Telecommunication Sector degrew by 2.7%. On Geographical front, Americas grew by 11.7% QoQ, Europe degrew by 8.4%, RoW degrew by 8.1% QoQ.

FINANCIAL SUMMARY (Consolidated)

| Y/E | Sales | EBITDA | PAT | EPS | P/E | RoE | RoCE | DPS |
|-------|---------|---------|---------|------|------|-----|------|------|
| March | (Rs Cr) | (Rs Cr) | (Rs Cr) | (Rs) | (x) | (%) | (%) | (Rs) |
| FY18 | 47,568 | 11,458 | 8,606 | 64.7 | 15.8 | 25% | 25% | 12 |
| FY19 | 60,427 | 13,968 | 10,127 | 74.6 | 13.7 | 26% | 24% | 10 |
| FY20E | 67,385 | 15,548 | 10,134 | 81.4 | 13.3 | 23% | 21% | 32 |
| FY21E | 70,831 | 17,808 | 11,470 | 89.5 | 12.2 | 24% | 22% | 34 |

Source: Company, Axis Securities, Consensus Estimates, CMP as on 20th Aug, 2019

PRICE PERFORMANCE



OmkarTanksale

omkar.tanksale@axissecurities.in





IBM partnership - driving growth and earnings momentum

HCL Tech has completed the acquisition of 7 products from IBM out of which 5 products were earlier under IP partnership and 2 products are new. Company has already paid \$ 81 crs on June 30, 2019, and will likely pay \$ 81.25 Crs after one year. The deal also has an earnout component of \$ 15 crs to be paid in three installments. This partnership will lead to goodwill of \$ 92 crs and intangible asset of \$ 125 crs adding to amortization. IBM product portfolio has EBITDA margin of 50%+ with amortization of ~20%, yielding EBIT margin of ~30%. The business has Q3 as the strongest quarter and Q2 as the weakest. We believe that IBM product business will help regain the operating margins over the longer run.

Key Highlights

- Financial services vertical reported muted growth for yet another quarter, the financial services vertical posted 0.5% QoQ growth due to client specific issues in two key accounts. However management indicated that 1 account is stabilizing and will likely see revival in H2 FY20 or in Q4 FY20.
- HCL launched new division viz HCL software which will be a part of products and platform and will
 house the IBM products along with several other software and IP assets.
- Management is expecting tax rate to be at 24%-26% for FY20.
- HCLT highlighted the selective approach it is adopting to sign deals in order to protect margin due to margin headwinds from deal transition costs and ER&D business

Mode 1-2-3 Highlights

| | Revenue (In \$ mn) | Revenue Mix | EBIT Margin | QoQ Growth |
|--------|-----------------------|-------------|-------------|---------------|
| Mode 1 | 1662 | 70% | 18% | 4% |
| Mode 2 | 444 | 19% | 13% | 4% |
| Mode 3 | 258 | 11% | 19% | 7% |
| Total | 2364 | 100% | 17 % | 4 % |





Geographical Mix

| | Q1 FY20 | Q4 FY19 | Q1 FY19 | QoQ | YOY |
|---------|---------|---------|---------|-------|-------|
| America | 68% | 63% | 64% | 480 | 370 |
| Europe | 26% | 30% | 28% | (380) | (220) |
| RoW | 6% | 7% | 8% | (110) | (120) |

Service Mix

| | Q1 FY20 | Q4 FY19 | Q1 FY19 | QoQ | YOY |
|------------------------------|---------|---------|---------|-------|-------|
| Application Services | 33% | 32% | 35% | 60 | (210) |
| Infrastructure Services | 39% | 38% | 37% | 140 | 160 |
| Business Services | 5% | 5% | 4% | (50) | 60 |
| Engineering and R&D Services | 24% | 26% | 24% | (160) | (20) |

Vertical Mix

| In (%) | Q1 FY20 | Q4 FY19 | Q1 FY19 | QoQ | YOY |
|---------------------------|---------|---------|---------|-------|-------|
| Financial Services | 20% | 21% | 24% | (80) | (350) |
| Manufacturing | 20% | 18% | 18% | 240 | 160 |
| Technology & Services | 19% | 19% | 18% | 20 | 70 |
| Retail & CPG | 10% | 10% | 9% | (50) | 40 |
| Telecommunication, Media | 8% | 9% | 7% | (40) | 90 |
| Lifesciences & Healthcare | 11% | 13% | 13% | (250) | (230) |
| Public Services | 11% | 11% | 11% | - | 60 |

Number of Clients

| In (%) | Q1 FY20 | Q4 FY19 | Q1 FY19 | QoQ | YOY |
|----------|---------|---------|---------|-----|-----|
| 100 Mn + | 12 | 10 | 9 | 20% | 33% |
| 50 Mn + | 29 | 29 | 32 | 0% | -9% |
| 20 Mn + | 93 | 95 | 87 | -2% | 7% |
| 10 Mn + | 172 | 166 | 162 | 4% | 6% |
| 5 Mn + | 293 | 283 | 267 | 4% | 10% |
| 1 Mn + | 633 | 623 | 571 | 2% | 11% |





Clinet Contribution

| | Q1 FY20 | Q4 FY19 | Q1 FY19 |
|----------------|---------|---------|---------|
| Top 5 Clients | 17% | 17% | 17% |
| Top 10 Clients | 24% | 24% | 25% |
| Top 20 Clients | 34% | 33% | 34% |


Employee Data

| In (%) | Q1 FY20 | Q4 FY19 | Q1 FY19 | QoQ | YOY |
|----------------------|---------|---------|---------|-----|-----|
| Total Employee Count | 143,900 | 137,965 | 124,121 | 4% | 16% |
| Technical | 132,384 | 126,717 | 113,404 | 4% | 17% |
| Support | 11,516 | 11,248 | 10,717 | 2% | 7% |
| Gross Addition | 16,332 | 14,249 | 12,558 | 15% | 30% |
| Attrition | 17.3% | 18.0% | 16.3% | | |
| Blended Utilization | 85.4% | 86.6% | 85.9% | | |


Valuations

Robust business structure, healthy deal pipeline and revitalization of key business segment make HCL Tech a safer bet to invest in. Rising demand across geographies and across different verticals helps HCL Tech to attain higher growth momentum. We assign 13.8x P/E multiple to its FY21E earnings of Rs. 89.5 per share which gives a target price of Rs. 1,235 per share, an upside of 15%.

HCL Tech-12M Fwd PE Band



HCL Tech 12M Fwd PE Chart



Source: Company, Axis Securities






Revenue growth




Net Profit growth




Source: Company, Axis Securities

Operating Margin



Total Deal wins (In Numbers)



Source: Company, Axis Securities





Results Update

| | Quarterly Performance | | | | |
|-------------------|-----------------------|--------|--------|-------------------|----------------|
| (Rs.Cr.) | Q1FY20 | Q4FY19 | Q1FY19 | % Change (QoQ) | % Change (YoY) |
| Revenues | 16425 | 15,990 | 13,878 | 3% | 18% |
| Direct Costs | 10920 | 10,421 | 9,106 | 5% | 20% |
| Gross Profits | 5505 | 5,568 | 4,771 | -1% | 15% |
| SG&A | 2105 | 1,972 | 1,546 | 7% | 36% |
| EBITDA | 3401 | 3,596 | 3,225 | -5% | 5% |
| EBITDA Margin | 21% | 22% | 23% | | |
| Depreciation | 595 | 558 | 496 | 7% | 20% |
| EBIT | 2806 | 3,039 | 2,729 | -8% | 3% |
| EBIT Margin | 17% | 19% | 20% | | |
| Forex Gains | 19 | 23 | 143 | -17% | |
| Other Income | 109 | 129 | 153 | -16% | |
| ЕВТ | 2934 | 2,568 | 3025 | 14% | -3% |
| Provision For Tax | 705 | 615 | 622 | 15% | 13% |
| ETR | 24% | 24% | 21% | | |
| Net Profit | 2220 | 2,568 | 2,403 | -14% | -8% |
| Net Profit Margin | 14% | 16% | 17% | | |
| EPS Diluted | 65.5 | 75.7 | 69 | | |

Source: Company, Axis Securities







Disclosures:

The following Disclosures are being made in compliance with the SEBI Research Analyst Regulations 2014 (herein after referred to as the Regulations).

- 1. Axis Securities Ltd. (ASL) is a SEBI Registered Research Analyst having registration no. INH000000297. ASL, the Research Entity (RE) as defined in the Regulations, is engaged in the business of providing Stock broking services, Portfolio Management Services, Depository participant services & distribution of various financial products. ASL is a subsidiary company of Axis Bank Ltd. Axis Bank Ltd. is a listed public company and one of India's largest private sector bank and has its various subsidiaries engaged in businesses of Asset management, NBFC, Merchant Banking, Trusteeship, Venture Capital, Stock Broking, the details in respect of which are available on www.axisbank.com.
- 2. ASL is registered with the Securities & Exchange Board of India (SEBI) for its stock broking & Depository participant business activities and with the Association of Mutual Funds of India (AMFI) for distribution of financial products and also registered with IRDA as a corporate agent for insurance business activity.
- 3. ASL has no material adverse disciplinary history as on the date of publication of this report.
- 4. I/We, OmkarTanksale, MBA (Finance), author/s and the name/s subscribed to this report, hereby certify that all of the views expressed in this research report accurately reflect my/our views about the subject issuer(s) or securities. I/We (Research Analyst) also certify that no part of my/our compensation was, is, or will be directly or indirectly related to the specific recommendation(s) or view(s) in this report. I/we or my/our relative or ASL does not have any financial interest in the subject company. Also I/we or my/our relative or ASL or its Associates may have beneficial ownership of 1% or more in the subject company at the end of the month immediately preceding the date of publication of the Research Report. Since associates of ASL are engaged in various financial service businesses, they might have financial interests or beneficial ownership in various companies including the subject company/companies mentioned in this report. I/we or my/our relative or ASL or its associate does not have any material conflict of interest. I/we have not served as director / officer, etc. in the subject company in the last 12-month period.

Any holding in stock - No


- 5. ASL has not received any compensation from the subject company in the past twelve months. ASL has not been engaged in market making activity for the subject company.
- 6. In the last 12-month period ending on the last day of the month immediately preceding the date of publication of this research report, ASL or any of its associates may have:
 - i. Received compensation for investment banking, merchant banking or stock broking services or for any other services from the subject company of this research report and / or;
 - ii. Managed or co-managed public offering of the securities from the subject company of this research report and / or;
 - iii. Received compensation for products or services other than investment banking, merchant banking or stock broking services from the subject company of this research report;

ASL or any of its associates have not received compensation or other benefits from the subject company of this research report or any other third-party in connection with this report.

Term& Conditions:

This report has been prepared by ASL and is meant for sole use by the recipient and not for circulation. The report and information contained herein is strictly confidential and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of ASL. The report is based on the facts, figures and information that are considered true, correct, reliable and accurate. The intent of this report is not recommendatory in nature. The information is obtained from publicly available media or other sources believed to be reliable. Such information has not been independently verified and no guaranty, representation of warranty, express or implied, is made as to its accuracy, completeness or correctness. All such information and opinions are subject to change without notice. The report is prepared solely for informational purpose and does not constitute an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments for the clients. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. ASL will not treat recipients as customers by virtue of their receiving this report.







| DEFINITION OF RATINGS | | | | | |
|-----------------------|--|--|--|--|--|
| Ratings | Expected absolute returns over 12-18 months | | | | |
| BUY | More than 10% | | | | |
| HOLD | Between 10% and -10% | | | | |
| SELL | Less than -10% | | | | |
| NOT RATED | We have forward looking estimates for the stock but we refrain from assigning valuation and recommendation | | | | |
| UNDER REVIEW | We will revisit our recommendation, valuation and estimates on the stock following recent events | | | | |
| NO STANCE | We do not have any forward looking estimates, valuation or recommendation for the stock | | | | |

Disclaimer:

Nothing in this report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to the recipient's specific circumstances. The securities and strategies discussed and opinions expressed, if any, in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient.

This report may not be taken in substitution for the exercise of independent judgment by any recipient. Each recipient of this report should make such investigations as it deems necessary to arrive at an independent evaluation of an investment in the securities of companies referred to in this report (including the merits and risks involved), and should consult its own advisors to determine the merits and risks of such an investment. Certain transactions, including those involving futures, options and other derivatives as well as non-investment grade securities involve substantial risk and are not suitable for all investors. ASL, its directors, analysts or employees do not take any responsibility, financial or otherwise, of the losses or the damages sustained due to the investments made or any action taken on basis of this report, including but not restricted to, fluctuation in the prices of shares and bonds, changes in the currency rates, diminution in the NAVs, reduction in the dividend or income, etc. Past performance is not necessarily a guide to future performance. Investors are advice necessarily a guide to future performance. Investors are advice necessarily a guide to future performance. Investors are advice necessarily in the securities markets. Actual results may differ materially from those set forth in projections. Forward-looking statements are not predictions and may be subject to change without notice.

ASL and its affiliated companies, their directors and employees may; (a) from time to time, have long or short position(s) in, and buy or sell the securities of the company(ies) mentioned herein or (b) be engaged in any other transaction involving such securities or earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or investment banker, lender/borrower to such company(ies) or may have any other potential conflict of interests with respect to any recommendation and other related information and opinions. Each of these entities functions as a separate, distinct and independent of each other. The recipient should take this into account before interpreting this document.

ASL and / or its affiliates do and seek to do business including investment banking with companies covered in its research reports. As a result, the recipients of this report should be aware that ASL may have a potential conflict of interest that may affect the objectivity of this report. Compensation of Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions. ASL may have issued other reports that are inconsistent with and reach different conclusion from the information presented in this report. The Research reports are also available & published on AxisDirect website.

Neither this report nor any copy of it may be taken or transmitted into the United State (to U.S. Persons), Canada, or Japan or distributed, directly or indirectly, in the United States or Canada or distributed or redistributed in Japan or to any resident thereof. If this report is inadvertently sent or has reached any individual in such country, especially, USA, the same may be ignored and brought to the attention of the sender. This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject ASL to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors.

The Disclosures of Interest Statement incorporated in this document is provided solely to enhance the transparency and should not be treated as endorsement of the views expressed in the report. The Company reserves the right to make modifications and alternations to this document as may be required from time to time without any prior notice. The views expressed are those of the analyst(s) and the Company may or may not subscribe to all the views expressed therein.

Copyright in this document vests with Axis Securities Limited.

Axis Securities Limited, Corporate office: Unit No. 2, Phoenix Market City, 15, LBS Road, Near Kamani Junction, Kurla (west), Mumbai-400070, Tel No. – 18002100808, Regd. off.- Axis House, 8th Floor, Wadia International Centre, PandurangBudhkar Marg, Worli, Mumbai – 400 025. Compliance Officer: AnandShaha, Email: compliance.officer@axisdirect.in, Tel No: 022- 4050 8080 .SEBI-Portfolio Manager Reg. No. INP000000654

